Table 5.
Exploratory biomarker analysis.
| Enrollment no. | Type of cancer | Best response | Maximal change (%) | Treatment duration (weeks) | Bx points | HGFa | p-ERK | cMET |
PD-L1 |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| + or – | + or – | + or – | Tumor | TIL | CPS, % | ||||||
| RB008 | Rectal cancer | SD | 15.4 | 22.6 | Pre | – | – | + (90%) | 5 | 5 | 10 |
| D29 | – | + (20%) | + (80%) | 15 | 15 | ||||||
| RB012 | Melanoma | SD | 2.3 | 23.3 | Pre | + (90%) | – | – | 2 | 1 | 3 |
| D29 | + (90%) | + (90%) | – | 1 | 0 | 1 | |||||
| RB013 | Colon cancer | SD | 18.3 | 15.7 | Pre | – | – | + (90%) | 10 | 1 | 11 |
| D29 | – | – | + (40%) | 5 | 3 | 8 | |||||
| RB014 | Colon cancer | SD | 12.8 | 14.4 | Pre | – | – | + (80%) | 0 | 0 | 0 |
| RB017 | Sebaceous carcinoma | SD | –1.2 | 15.6 | Pre | – | + (100%) | – | 0 | 0 | 0 |
| D29 | – | + (70%) | – | 0 | 1 | 1 | |||||
| RB009 | Gastric cancer | PD | 21.4 | 4.3 | Pre | – | – | – | 10 | 0 | 10 |
| RB010 | Colon cancer | PD | 26.7 | 4.0 | Pre | – | + (60%) | + (90%) | 0 | 2 | 2 |
| D29_1 | – | + (80%) | – | 0 | 0 | 0 | |||||
| D29_2 | – | – (95%) | – | 0 | 0 | 0 | |||||
| RB015 | Melanoma | PD | 101.0 | 5.6 | Pre | – | + (70%) | – | 1 | 1 | 2 |
| RB016 | Sarcoma | PD | 210.2 | 3.7 | Pre | – | – | – | 8 | 3 | 11 |